EP 4142718 A1 20230308 - MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE
Title (en)
MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE
Title (de)
PHARMAZEUTISCHE FORMULIERUNG MIT MODIFIZIERTER FREISETZUNG MIT HYDROXYPROPYLCELLULOSE
Title (fr)
FORMULATION PHARMACEUTIQUE À LIBÉRATION MODIFIÉE COMPRENANT DE L'HYDROXYPROPYLCELLULOSE
Publication
Application
Priority
- US 202063019215 P 20200501
- US 2021029581 W 20210428
Abstract (en)
[origin: WO2021222369A1] The present disclosure relates to hydroxypropyl cellulose (HPC) having a molar substitution of from about 3.0 to about 3.9, a weight average molecular weight of from about 800,000 to about 2,000,000 Daltons, and a volume average particle size of less than 100 μm, and modified release formulations derived therefrom.
IPC 8 full level
A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01)
CPC (source: EP IL KR)
A61K 9/2054 (2013.01 - EP IL KR); A61K 31/192 (2013.01 - EP IL KR); A61K 31/5415 (2013.01 - KR); A61K 31/549 (2013.01 - EP IL KR); A61K 47/38 (2013.01 - EP IL KR); C08B 11/08 (2013.01 - EP KR); C08L 1/284 (2013.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021222369 A1 20211104; BR 112022022107 A2 20230228; CA 3176772 A1 20211104; CN 115996718 A 20230421; EP 4142718 A1 20230308; EP 4142718 A4 20240529; IL 297810 A 20221201; JP 2023524517 A 20230612; KR 20230005317 A 20230109; MX 2022013552 A 20221130
DOCDB simple family (application)
US 2021029581 W 20210428; BR 112022022107 A 20210428; CA 3176772 A 20210428; CN 202180045957 A 20210428; EP 21795764 A 20210428; IL 29781022 A 20221030; JP 2022566421 A 20210428; KR 20227041714 A 20210428; MX 2022013552 A 20210428